BeiGene (NASDAQ:ONC) Full Year 2024 Results

Key Financial Results

• Revenue: US$3.81b (up 55% from FY 2023).
• Net loss: US$644.8m (loss narrowed by 27% from FY 2023).
• US$6.12 loss per share (improved from US$8.45 loss in FY 2023).

ONC Products In Clinical Trials

• Phase I: 33.
• Phase II: 17.
• Phase III: 13.

ONC Post-Clinical Trial Products

• Pre-registration: 8.
• Approved (during full year): 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

BeiGene Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) missed analyst estimates by 9.5%.

The primary driver behind last 12 months revenue was the United States (U.S) segment contributing a total revenue of US$1.96b (51% of total revenue). The largest operating expense was Research & Development (R&D) costs, amounting to US$1.95b (51% of total expenses). Explore how ONC's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 5.0% from a week ago.

Valuation

If you are seeking undervalued stocks, our analysis of 6 valuation measures indicates BeiGene could be a good place to look. You can access our in-depth analysis and discover what the outlook is like for the stock by clicking here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.